8-K: KORU Medical Systems Announces Record Revenues and Positive Cash Flow in Preliminary 2024 Results

KORU Medical Systems reports record full-year and quarterly revenues, along with positive cash flow for the fourth quarter of 2024.

Summary

• KORU Medical Systems has released preliminary unaudited financial results for the fourth quarter and full year of 2024.
• The company expects net revenues of $8.9 million for the fourth quarter, a 23% increase year-over-year.
• Full-year 2024 net revenues are projected to be $33.7 million, an 18% increase compared to the previous year.
• KORU Medical achieved positive cash flow of $0.8 million in the fourth quarter.
• The company's full-year cash burn was $1.9 million, a 67% improvement over the prior year.
• The company plans to release its final fourth quarter and full year 2024 financial results in early March 2025.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the record revenues, positive cash flow, and significant improvement in cash burn. The management's comments are also optimistic about future growth.

Positives

• The company experienced significant revenue growth in both the fourth quarter and full year of 2024.
• KORU Medical demonstrated improved cash management, achieving positive cash flow in the fourth quarter and reducing the full-year cash burn.
• The company is expanding its international presence and making progress in adding new drug therapies to its label.
• KORU Medical is winning market share in the US market.

Risks

• The preliminary financial results are subject to change based on the completion of closing and review procedures.
• The company's future performance is subject to risks and uncertainties, including sales expansion into new regions.

Future Outlook

KORU Medical expects to carry its fourth-quarter momentum into 2025 and capitalize on near-term catalysts to become a global leader in drug delivery.

Management Comments

• Linda Tharby, President and CEO of KORU Medical, stated that she is proud of the growth achieved in the fourth quarter and 2024.
• Management highlighted the execution of their strategic plan, including winning market share in the US, expanding internationally, and progressing towards adding new drug therapies to their label.
• Management also noted the improvement in margins and disciplined use of cash.

Industry Context

The announcement reflects a positive trend in the medical technology sector, particularly in companies focused on innovative drug delivery solutions. KORU Medical's growth suggests a strong market demand for its subcutaneous infusion systems.

Comparison to Industry Standards

• While specific competitor data is not provided, KORU Medical's 18% revenue growth for the full year and 23% growth in Q4 indicates a strong performance compared to industry averages for medical device companies.
• The positive cash flow in Q4 and significant reduction in cash burn for the year are also positive indicators, suggesting efficient operations and financial management.
• Companies like Insulet and Tandem Diabetes Care, which focus on drug delivery, have seen similar growth trajectories, but KORU's focus on subcutaneous infusion provides a unique market position.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and improved financial performance.
• Employees may be motivated by the company's success and positive outlook.
• Customers and patients may benefit from the company's continued innovation and expansion of its product offerings.
• Suppliers and creditors may view the company as a more stable and reliable partner due to its improved financial health.

Next Steps

• KORU Medical plans to release its final fourth quarter and full year 2024 financial results in early March 2025.
• The company will continue to execute its strategic plan, focusing on market share gains, international expansion, and adding new drug therapies.

Key Dates

Keywords

medical technology, subcutaneous infusion, revenue growth, cash flow, financial results, drug delivery, KORU Medical